Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track NERV with free AI briefings, catalyst countdowns, and dilution alerts.

NERV · Minerva Neurosciences, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$76.9M Cash on Hand
21.5mo Cash Runway
Follow NERV by email Get an email when NERV reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NERV, unsubscribe in one click. Privacy

📣 What NERV Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Tramadol Thyroid Cancer Phase 4 · NCT03469310 Completed
Tylenol #3 Oral Tablet Thyroid Cancer Phase 4 · NCT03469310 Completed
Roluperidone Negative Symptoms of Schizophrenia Phase 3 · NCT07565428 Recruiting
MIN-117 2.5 mg Major Depressive Disorder Phase 2 · NCT03446846 Completed
huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T… Metastatic Breast Cancer Phase 1 · NCT04020575 Recruiting
huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T… Metastatic Breast Cancer Phase 1 · NCT04020575 Recruiting
MIN-101 Healthy Subjects Phase 1 · NCT03038646 Completed

Also used in these trials (approved or third-party drugs, not NERV's own candidates): Acetaminophen, Aripiprazole, Olanzapine, Risperidone.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

NERV holds $76.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $10.7M/quarter from operations, an estimated runway of 21.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 33 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NERV files for a raise →

👥 Who Owns NERV

Insiders 0% Other 5%+ holders 26.3% Institutions (91 holders) 73.7% Public and other holders 0%
HolderTypeShares% of sharesAs of
Federated Hermes, Inc. Institution (13G, 5%+) 8,690,926 17.44% 2026-06-30
Vivo Opportunity Fund Holdings, L.P. 5%+ holder (13G) 8,591,572 17.24% 2025-12-23
Coastlands Capital LP Institution (13G, 5%+) 5,052,055 10.14% 2026-09-30
BALYASNY ASSET MANAGEMENT L.P. Institution (13G, 5%+) 4,769,981 9.57% 2026-09-30
Farallon Capital Management, L.L.C. Institution (13G, 5%+) 4,730,000 9.49% 2026-06-30
Dapice Joshua J. 5%+ holder (13G) 4,539,854 9.11% 2025-12-31
Logos Global Management LP Institution (13G, 5%+) 4,435,444 8.90% 2025-12-23
JANUS HENDERSON GROUP PLC Institution (13G, 5%+) 4,307,759 8.64% 2026-03-31
Adage Capital Management, L.P. Institution (13G, 5%+) 2,838,000 5.69% 2025-12-31
BlackRock, Inc. Institution (13G, 5%+) 2,450,284 4.92% 2026-09-30
Joseph H. Reilly
Chief Operating Officer
Insider 20,872 0.04% 2026-08-10
Anthony Aliquo
Chief Accounting Officer
Insider 1,683 0.00% 2026-08-10

Share count 49,835,241 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full NERV picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NERV and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.